Metastatic and triple-negative breast cancer: challenges and treatment options

被引：499

作者：

Al-Mahmood, Sumayah ^{[1
]}

Sapiezynski, Justin ^{[1
]}

Garbuzenko, Olga B. ^{[1
]}

Minko, Tamara ^{[1
,2
,3
]}

机构：

[1] Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA

[2] Rutgers Canc Inst, New Brunswick, NJ 08903 USA

[3] Rutgers State Univ, Environm & Occupat Hlth Sci Inst, Rutgers, Piscataway, NJ 08854 USA

来源：

DRUG DELIVERY AND TRANSLATIONAL RESEARCH | 2018年 / 8卷 / 05期

基金：

美国国家卫生研究院;

关键词：

Liposomes; EGFR; siRNA; Gefitinib; Combinatorial treatment of breast cancer; PHASE-II TRIAL; CIRCULATING TUMOR-CELLS; ADO-TRASTUZUMAB EMTANSINE; CAPECITABINE COMBINATION THERAPY; GEMCITABINE PLUS VINORELBINE; OVARIAN-FUNCTION SUPPRESSION; ORAL VINORELBINE; RISK-FACTORS; AROMATASE INHIBITOR; PRETREATED PATIENTS;

D O I：

10.1007/s13346-018-0551-3

中图分类号：

TH7 [仪器、仪表];

学科分类号：

080401 [精密仪器及机械];

摘要：

The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10-20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.

引用

页码：1483 / 1507

页数：25

共 263 条

[1]

Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results [J].

Aapro, Matti ;

Finek, Jindrich .

CANCER TREATMENT REVIEWS, 2012, 38 (02) :120-126

[2]

Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases [J].

Addeo, Raffaele ;

Sperlongano, Pasquale ;

Montella, Liliana ;

Vincenzi, Bruno ;

Carraturo, Marco ;

Iodice, Patrizia ;

Russo, Paola ;

Parlato, Ciro ;

Salzano, Antonio ;

Cennamo, Gregorio ;

Lombardi, Angela ;

Sperlongano, Rossella ;

Del Prete, Salvatore ;

Caraglia, Michele .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) :603-609

[3]

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study [J].

Addison, Christina L. ;

Pond, Gregory R. ;

Cochrane, Brandy ;

Zhao, Huijun ;

Chia, Stephen K. ;

Levine, Mark N. ;

Clemons, Mark .

JOURNAL OF BONE ONCOLOGY, 2015, 4 (02) :47-53

[4]

RETRACTED: Down-Regulation of uPA and uPAR by 3,3′-Diindolylmethane Contributes to the Inhibition of Cell Growth and Migration of Breast Cancer Cells (Retracted article. See vol. 117, pg. 1959, 2016) [J].

Ahmad, Aamir ;

Kong, Dejuan ;

Wang, Zhiwei ;

Sarkar, Sanila. H. ;

Banerjee, Sanjeev ;

Sarkar, Fazlul H. .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 108 (04) :916-925

[5]

Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor [J].

Al-Ejeh, Fares ;

Shi, Wei ;

Miranda, Mariska ;

Simpson, Peter T. ;

Vargas, Ana Cristina ;

Song, Sarah ;

Wiegmans, Adrian P. ;

Swarbrick, Alex ;

Welm, Alana L. ;

Brown, Michael P. ;

Chenevix-Trench, Georgia ;

Lakhani, Sunil R. ;

Khanna, Kum Kum .

JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (06) :913-921

[6]

Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[7]

Self-renewal and solid tumor stem cells [J].

Al-Hajj, M ;

Clarke, MF .

ONCOGENE, 2004, 23 (43) :7274-7282

[8]

Dual roles for immune metagenes in breast cancer prognosis and therapy prediction [J].

Alistar, Angela ;

Chou, Jeff W. ;

Nagalla, Srikanth ;

Black, Michael A. ;

D'Agostino, Ralph, Jr. ;

Miller, Lance D. .

GENOME MEDICINE, 2014, 6

[9]

Gemcitabine and taxanes in metastatic breast cancer [J].

Amadori, D. ;

Cecconetto, L. .

ANNALS OF ONCOLOGY, 2006, 17 :V173-V176

[10]

Metastatic Breast Cancer to the Gastrointestinal Tract: Report of Five Cases and Review of the Literature [J].

Ambroggi, Massimo ;

Stroppa, Elisa Maria ;

Mordenti, Patrizia ;

Biasini, Claudia ;

Zangrandi, Adriano ;

Michieletti, Emanuele ;

Belloni, Elena ;

Cavanna, Luigi .

INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012

← 1 2 3 4 5 6 7 8 9 10 →